Literature DB >> 24737283

Unmet need in Behcet's disease: most patients in routine follow-up continue to have oral ulcers.

Fatma Alibaz-Oner1, Gonca Mumcu, Zeynep Kubilay, Gulsen Ozen, Gulce Celik, Aslı Karadeniz, Meryem Can, Sibel Yilmaz Oner, Nevsun Inanc, Pamir Atagunduz, Tulin Ergun, Haner Direskeneli.   

Abstract

The clinical course of Behcet's disease (BD) as a multisystemic disorder with a remitting-relapsing nature is insufficiently explored. As complete remission should be aimed in all inflammatory diseases, we investigated the frequency of complete remission in patients with BD followed in long-term, routine practice. In this retrospective study, 258 patients with BD who were regularly followed in outpatient clinics were assessed. The demographic and clinical data for active organ manifestations and treatment protocols were evaluated, and "complete remission" for this study was defined as no sign of any disease manifestation in the current visit and the preceding month. Two hundred fifty-eight patients with BD (F/M 130/128, mean age 41.1 ± 11.5 years) were included to the study. Mucocutaneous disease was present in 48.4 % (n = 125). Mean visit number was 6.8 ± 2.7, and mean follow-up duration was 45.8 ± 36.5 months. Patients were clinically active in 67.2 % (n = 1,182) of the total visits (n = 1,757), which increased to 75.6 % (68.1-90.3) when the month preceding the visit was also included. The most common active manifestation was oral ulcers (39.4-63.2 %) followed by other mucocutaneous manifestations and musculoskeletal involvement. When multivariate analysis was performed, oral ulcers, which are the main cause of the clinical activity, negatively correlated with immunosuppressive treatments (β = -0.356, p < 0.000) and age (β = -0.183, p = 0.04). It is fairly difficult to achieve complete remission in BD with current therapeutic regimens. The reluctance of the clinician to be aggressive for some BD manifestations with low morbidity, such as mucocutaneous lesions and arthritis, might be influencing the continuous, low-disease activity state, especially due to oral ulcers, in BD patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24737283     DOI: 10.1007/s10067-014-2585-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  17 in total

Review 1.  Behçet's disease.

Authors:  T Sakane; M Takeno; N Suzuki; G Inaba
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

2.  Clinical and immunological effects of azithromycin in Behçet's disease.

Authors:  G Mumcu; T Ergun; Y Elbir; E Eksioglu-Demiralp; S Yavuz; T Atalay; H Direskeneli
Journal:  J Oral Pathol Med       Date:  2005-01       Impact factor: 4.253

Review 3.  Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature.

Authors:  Nicolò Pipitone; Ignazio Olivieri; Angela Padula; Salvatore D'angelo; Angelo Nigro; Giulio Zuccoli; Luigi Boiardi; Carlo Salvarani
Journal:  Arthritis Rheum       Date:  2008-02-15

Review 4.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

5.  Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease.

Authors:  Yoon Suk Jung; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  J Clin Gastroenterol       Date:  2012 May-Jun       Impact factor: 3.062

6.  Treat-to-target in systemic lupus erythematosus: where are we today?

Authors:  Marta Mosca; Dimitrios T Boumpas; Ian N Bruce; Ricard Cervera; Laszlo Czirjak; Thomas Dörner; Frédéric Houssiau; Soren Jacobsen; Matthias Schneider; Josef S Smolen; Alexandre E Voskuyl; Ronald F van Vollenhoven
Journal:  Clin Exp Rheumatol       Date:  2012-11-20       Impact factor: 4.473

7.  A composite index for determining the impact of oral ulcer activity in Behcet's disease and recurrent aphthous stomatitis.

Authors:  G Mumcu; H Sur; N Inanc; U Karacayli; H Cimilli; N Sisman; T Ergun; H Direskeneli
Journal:  J Oral Pathol Med       Date:  2009-07-15       Impact factor: 4.253

Review 8.  The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet's disease.

Authors:  G Mumcu; N Inanc; S Yavuz; H Direskeneli
Journal:  Clin Exp Rheumatol       Date:  2007 Jul-Aug       Impact factor: 4.473

9.  Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease.

Authors:  Travis Hughes; Patrick Coit; Adam Adler; Vuslat Yilmaz; Kenan Aksu; Nursen Düzgün; Gokhan Keser; Ayse Cefle; Ayten Yazici; Andac Ergen; Erkan Alpsoy; Carlo Salvarani; Bruno Casali; Ina Kötter; Javier Gutierrez-Achury; Cisca Wijmenga; Haner Direskeneli; Güher Saruhan-Direskeneli; Amr H Sawalha
Journal:  Nat Genet       Date:  2013-02-10       Impact factor: 38.330

10.  Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire.

Authors:  Boulos Haraoui; Josef S Smolen; Daniel Aletaha; Ferdinand C Breedveld; Gerd Burmester; Catalin Codreanu; José Pereira Da Silva; Maarten de Wit; Maxime Dougados; Patrick Durez; Paul Emery; João Eurico Fonseca; Allan Gibofsky; Juan Gomez-Reino; Winfried Graninger; Vedat Hamuryudan; Maria José Jannaut Peña; Joachim Kalden; Tore K Kvien; Ieda Laurindo; Emilio Martin-Mola; Carlomaurizio Montecucco; Pedro Santos Moreno; Karel Pavelka; Gyula Poor; Mario H Cardiel; Ewa Stanislawska-Biernat; Tsutomu Takeuchi; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2011-07-29       Impact factor: 19.103

View more
  11 in total

1.  Oral ulcer activity in Behcet's disease: Poor medication adherence is an underestimated risk factor.

Authors:  Gonca Mumcu; Fatma Alibaz-Öner; Sibel Yılmaz Öner; Gülsen Özen; Pamir Atagündüz; Nevsun İnanç; Leyla Köksal; Tülin Ergun; Haner Direskeneli
Journal:  Eur J Rheumatol       Date:  2017-06-01

2.  Development of de novo major involvement during follow-up in Behçet's syndrome.

Authors:  Rosaria Talarico; Luca Cantarini; Anna d'Ascanio; Michele Figus; Benedetta Favati; Chiara Baldini; Chiara Tani; R Neri; Stefano Bombardieri; Marta Mosca
Journal:  Clin Rheumatol       Date:  2015-03-08       Impact factor: 2.980

Review 3.  Behçet syndrome: a contemporary view.

Authors:  Hasan Yazici; Emire Seyahi; Gulen Hatemi; Yusuf Yazici
Journal:  Nat Rev Rheumatol       Date:  2018-01-03       Impact factor: 20.543

Review 4.  Phenotypes in Behçet's syndrome.

Authors:  Emire Seyahi
Journal:  Intern Emerg Med       Date:  2019-02-11       Impact factor: 3.397

Review 5.  Triggering agents and microbiome as environmental factors on Behçet's syndrome.

Authors:  Gonca Mumcu; Haner Direskeneli
Journal:  Intern Emerg Med       Date:  2018-12-06       Impact factor: 3.397

Review 6.  Advances in the Treatment of Behcet's Disease.

Authors:  Fatma Alibaz-Oner; Haner Direskeneli
Journal:  Curr Rheumatol Rep       Date:  2021-05-20       Impact factor: 4.592

7.  Behçet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses.

Authors:  Fatma Alibaz-Oner; Asl Karadeniz; Sema Ylmaz; Ayşe Balkarl; Gezmiş Kimyon; Ayten Yazc; Muhammet Çnar; Sedat Ylmaz; Fatih Yldz; Şule Yaşar Bilge; Emre Bilgin; Belkis Nihan Coskun; Ahmet Omma; Gözde Yldrm Çetin; Yonca Çağatay; Yaşar Karaaslan; Mehmet Sayarlioğlu; Yavuz Pehlivan; Umut Kalyoncu; Ömer Karadağ; Timuçin Kaşifoğlu; Eren Erken; Salih Pay; Ayşe Çefle; Bünyamin Kisacik; Ahmet Mesut Onat; Veli Çobankara; Haner Direskeneli
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

8.  The assessment of contributing factors to oral ulcer presence in Behçet's disease: Dietary and non-dietary factors.

Authors:  Merve İris; Ezgi Özçıkmak; Aysun Aksoy; Fatma Alibaz-Öner; Nevsun İnanç; Tülin Ergun; Haner Direskeneli; Gonca Mumcu
Journal:  Eur J Rheumatol       Date:  2018-10-12

9.  Does illness perception associate with disease symptoms in Behçet's disease?

Authors:  Gonca Mumcu; Fedayi Yağar; Fatma Alibaz-Öner; Nevsun İnanç; Haner Direskeneli; Tulin Ergun
Journal:  Intern Emerg Med       Date:  2018-11-30       Impact factor: 3.397

Review 10.  Behçet's syndrome: providing integrated care.

Authors:  Sinem Nihal Esatoglu; Zekayi Kutlubay; Didar Ucar; Ibrahim Hatemi; Ugur Uygunoglu; Aksel Siva; Gulen Hatemi
Journal:  J Multidiscip Healthc       Date:  2017-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.